Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 3—March 2008

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands

Jakko van Ingen*†Comments to Author , Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
Author affiliations: *Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands; †National Institute for Public Health and the Environment, Bilthoven, the Netherlands;

Main Article

Table 2

Baseline in vitro susceptibility of 47 primary isolates from 42 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 through March 2005

Susceptibility Drug, no. (%), MIC
Isoniazid Rifampin Ethambutol
Susceptible 9 (21), MIC 0.2 mg/L 29 (69), MIC <1mg/L 5 (12), MIC 5 mg/L
Intermediate 32 (76), MIC 0.5–1.0 mg/L 11 (26), MIC 10 mg/L
Resistant 1 (2), MIC >1 mg/L 13 (31), MIC >1 mg/L 26 (62), MIC >10 mg/L

Main Article

Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.